Literature DB >> 30668633

Long-term exposure to anticholinergic and sedative medications and cognitive and physical function in later life.

Hans Wouters1,2, Sarah N Hilmer3, Danijela Gnjidic4, Jos P Van Campen5, Martina Teichert6, Helene G Van Der Meer1, Laura A Schaap7, Martijn Huisman8,9, Hannie C Comijs10, Petra Denig11, Claudine J Lamoth12, Katja Taxis1.   

Abstract

Background: Anticholinergic and sedative medications are frequently prescribed to older individuals. These medications are associated with short-term cognitive and physical impairment, but less is known about long-term associations. We therefore examined over twenty years whether cumulative exposure to these medications was related to poorer cognitive and physical functioning.
Methods: Older adult participants of the Longitudinal Aging Study Amsterdam (LASA) were followed from 1992-2012. On 7 measurement occasions, cumulative exposure to anticholinergic and sedative medications was quantified with the Drug Burden Index (DBI), a linear additive pharmacological dose-response model. Cognitive functioning was assessed with the Mini Mental State Examination (MMSE), Alphabet Coding Task (ACT, 3 trials), Auditory Verbal Learning Test (AVLT, learning and retention condition), and Raven Colored Progressive Matrices (RCPM, 2 trials). Physical functioning was assessed with the Walking Test (WT), Cardigan Test (CT), Chair Stands Test (CST), Balance Test (BT), and self-reported Functional Independence (FI). Data were analyzed with linear mixed models adjusted for age, education, sex, living with a partner, BMI, depressive symptoms, co-morbidities (cardiovascular disease, diabetes, cancer, COPD, osteoarthritis, CNS diseases), and prescribed medications.
Results: Longitudinal associations were found of the DBI with poorer cognitive functioning (less items correct on the 3 ACT trials, AVLT learning condition, and the 2 RCPM trials) and with poorer physical functioning (longer completion time on the CT, CST, and lower self-reported FI). Conclusions: This longitudinal analysis of data collected over 20 years, showed that higher long-term cumulative exposure to anticholinergic and sedative medications was associated with poorer cognitive and physical functioning.

Entities:  

Year:  2019        PMID: 30668633     DOI: 10.1093/gerona/glz019

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  11 in total

1.  The Effect of Cumulative Anticholinergic Use on the Cognitive Function of Older Adults: Results from the Personality and Total Health (PATH) Through Life Study.

Authors:  Malinee Neelamegam; Janice Zgibor; Henian Chen; Kathleen O'rourke; Chighaf Bakour; Lakshminarayan Rajaram; Kaarin J Anstey
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-09-16       Impact factor: 6.053

2.  The relationship between 19-year trends in medication use and changes in physical function among women in the mid-life: A Study of Women's Health Across the Nation pharmacoepidemiology study.

Authors:  Daniel H Solomon; Leah Santacroce; Alicia Colvin; Yinjuan Lian; Kristine Ruppert; Kazuki Yoshida
Journal:  Pharmacoepidemiol Drug Saf       Date:  2021-09-21       Impact factor: 2.732

3.  The cognitive effects of anticholinergic drugs on apolipoprotein ε4 carriers and noncarriers in the Wisconsin Registry for Alzheimer's Prevention study.

Authors:  Brian G Collin; Dheeraj Raju; Steven Katsikas
Journal:  Neuropsychology       Date:  2021-02       Impact factor: 3.295

4.  Anticholinergic burden: First comprehensive analysis using claims data shows large variation by age and sex.

Authors:  Jonas Reinold; Malte Braitmaier; Oliver Riedel; Ulrike Haug
Journal:  PLoS One       Date:  2021-06-30       Impact factor: 3.240

5.  Frail Older Persons' Experiences of Information and Participation in Hospital Care.

Authors:  Berit Forsman; Ann Svensson
Journal:  Int J Environ Res Public Health       Date:  2019-08-08       Impact factor: 3.390

6.  Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models.

Authors:  Sweilem B Al Rihani; Malavika Deodhar; Lucy I Darakjian; Pamela Dow; Matt K Smith; Ravil Bikmetov; Jacques Turgeon; Veronique Michaud
Journal:  Drugs Aging       Date:  2021-11-09       Impact factor: 3.923

7.  Deprescribing to reduce polypharmacy: study protocol for a randomised controlled trial assessing deprescribing of anticholinergic and sedative drugs in a cohort of frail older people living in the community.

Authors:  Ulrich Bergler; Nagham J Ailabouni; John W Pickering; Sarah N Hilmer; Dee Mangin; Prasad S Nishtala; Hamish Jamieson
Journal:  Trials       Date:  2021-11-03       Impact factor: 2.279

8.  Determinants and consequences of polypharmacy in patients with a depressive disorder in later life.

Authors:  Carlijn Wiersema; Richard C Oude Voshaar; Rob H S van den Brink; Hans Wouters; Peter Verhaak; Hannie C Comijs; Hans W Jeuring
Journal:  Acta Psychiatr Scand       Date:  2022-04-29       Impact factor: 7.734

9.  Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome.

Authors:  Martin Taylor-Rowan; Sophie Edwards; Anna H Noel-Storr; Jenny McCleery; Phyo K Myint; Roy Soiza; Carrie Stewart; Yoon Kong Loke; Terry J Quinn
Journal:  Cochrane Database Syst Rev       Date:  2021-05-05

10.  Anticholinergic Burden, Sleep Quality and Health Outcomes in Malaysian Aged Care Home Residents.

Authors:  Suresh Kumar; Syed Shahzad Hasan; Pei Se Wong; David Weng Kwai Chong; Therese Kairuz
Journal:  Pharmacy (Basel)       Date:  2019-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.